Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582713

Authors

Eliot B Blatt

Ganesh V Raj

Affiliations

Soon will be listed here.

Abstract

An estimated 30,000 men in the United States will die of metastatic prostate cancer (PCa) each year due to the development of therapy resistance, most notably resistance to second-generation antiandrogen enzalutamide. The vast majority of PCa is driven by the androgen receptor (AR). Enzalutamide is an AR antagonist, which extends patient survival and is widely used in the clinic for the treatment of castration-resistant prostate cancer (CRPC); however, many patients will have primary or develop acquired resistance and continue to progress. Characterization of the molecular mechanisms of enzalutamide resistance provides insight into potentially efficacious therapies for enzalutamide-resistant CRPC (ER-CRPC). Understanding these mechanisms is critical for the identification of biomarkers predictive of therapy resistance and the development of therapeutic strategies to target ER-CRPC.

Citing Articles

Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer Cells.

Goode E, Orozco-Moreno M, Hodgson K, Nabilah A, Murali M, Peng Z Cancers (Basel). 2024; 16(17).

PMID: 39272811 PMC: 11393965. DOI: 10.3390/cancers16172953.

High Mobility Group AT-hook 2: A Biomarker Associated with Resistance to Enzalutamide in Prostate Cancer Cells.

Liadi Y, Campbell T, Hwang B, Elliott B, Odero-Marah V Cancers (Basel). 2024; 16(15).

PMID: 39123360 PMC: 11311100. DOI: 10.3390/cancers16152631.

A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer.

Desai K, Serritella A, Stadler W, ODonnell P, Sweis R, Szmulewitz R Clin Cancer Res. 2024; 30(11):2384-2392.

PMID: 38536082 PMC: 11147727. DOI: 10.1158/1078-0432.CCR-23-3636.

Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC.

Panja S, Truica M, Yu C, Saggurthi V, Craige M, Whitehead K Nat Commun. 2024; 15(1):352.

PMID: 38191557 PMC: 10774320. DOI: 10.1038/s41467-024-44686-5.

UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance.

Rodriguez Tirado C, Wang C, Li X, Deng S, Gonzalez J, Johnson N Oncogene. 2023; 43(4):265-280.

PMID: 38030789 PMC: 10798893. DOI: 10.1038/s41388-023-02890-5.

References

Hsieh C, Botta G, Gao S, Li T, Van Allen E, Treacy D . PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Res. 2015; 75(10):1944-8. PMC: 4433564. DOI: 10.1158/0008-5472.CAN-14-3602. View

Bevan C, Hoare S, Claessens F, Heery D, Parker M . The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol. 1999; 19(12):8383-92. PMC: 84931. DOI: 10.1128/MCB.19.12.8383. View

Massie C, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L . The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011; 30(13):2719-33. PMC: 3155295. DOI: 10.1038/emboj.2011.158. View

Veldscholte J, Berrevoets C, Ris-Stalpers C, Kuiper G, Jenster G, Trapman J . The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol. 1992; 41(3-8):665-9. DOI: 10.1016/0960-0760(92)90401-4. View

Beltran H, Rickman D, Park K, Suk Chae S, Sboner A, MacDonald T . Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2012; 1(6):487-95. PMC: 3290518. DOI: 10.1158/2159-8290.CD-11-0130. View

Bishop J, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H . The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discov. 2016; 7(1):54-71. DOI: 10.1158/2159-8290.CD-15-1263. View

Tran C, Ouk S, Clegg N, Chen Y, Watson P, Arora V . Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009; 324(5928):787-90. PMC: 2981508. DOI: 10.1126/science.1168175. View

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

Mostaghel E, Marck B, Plymate S, Vessella R, Balk S, Matsumoto A . Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011; 17(18):5913-25. PMC: 3184252. DOI: 10.1158/1078-0432.CCR-11-0728. View

10.

Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson P, True L . Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One. 2011; 6(11):e27970. PMC: 3219707. DOI: 10.1371/journal.pone.0027970. View

11.

Hu R, Isaacs W, Luo J . A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate. 2011; 71(15):1656-67. PMC: 3360954. DOI: 10.1002/pros.21382. View

12.

Nadiminty N, Chun J, Lou W, Lin X, Gao A . NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate. 2008; 68(16):1725-33. DOI: 10.1002/pros.20839. View

13.

Rathkopf D, Morris M, Fox J, Danila D, Slovin S, Hager J . Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013; 31(28):3525-30. PMC: 3782148. DOI: 10.1200/JCO.2013.50.1684. View

14.

Mohler J, Titus M, Bai S, Kennerley B, Lih F, Tomer K . Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res. 2011; 71(4):1486-96. PMC: 3075600. DOI: 10.1158/0008-5472.CAN-10-1343. View

15.

Li Y, Alsagabi M, Fan D, Bova G, Tewfik A, Dehm S . Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res. 2011; 71(6):2108-17. PMC: 3059379. DOI: 10.1158/0008-5472.CAN-10-1998. View

16.

Miao L, Yang L, Li R, Rodrigues D, Crespo M, Hsieh J . Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in Prostate Cancer. Cancer Res. 2017; 77(11):3101-3112. DOI: 10.1158/0008-5472.CAN-16-2169. View

17.

Savory J, Prefontaine G, Lamprecht C, Liao M, Walther R, Lefebvre Y . Glucocorticoid receptor homodimers and glucocorticoid-mineralocorticoid receptor heterodimers form in the cytoplasm through alternative dimerization interfaces. Mol Cell Biol. 2001; 21(3):781-93. PMC: 86670. DOI: 10.1128/MCB.21.3.781-793.2001. View

18.

Alanee S, Moore A, Nutt M, Holland B, Dynda D, El-Zawahry A . Contemporary Incidence and Mortality Rates of Neuroendocrine Prostate Cancer. Anticancer Res. 2015; 35(7):4145-50. View

19.

Hu R, Dunn T, Wei S, Isharwal S, Veltri R, Humphreys E . Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009; 69(1):16-22. PMC: 2614301. DOI: 10.1158/0008-5472.CAN-08-2764. View

20.

Kiemer A, Takeuchi K, Quinlan M . Identification of genes involved in epithelial-mesenchymal transition and tumor progression. Oncogene. 2001; 20(46):6679-88. DOI: 10.1038/sj.onc.1204872. View